UDP Glucuronosyltransferase, 1A1
| Order Code: | UGT1A1 |
| Epic Lab Code: | LAB4221 |
| Order Form: | A-1a Miscellaneous Request or Epic Req |
Commercial Mail-out Laboratory
6240 RCP
356-3527
6240 RCP
356-3527
Specimen:
Whole blood
Collection Medium:
![]() |
| Lavender top tube 3 mL (EDTA) |
Alternate
Collection Media:
Pink top tube, Yellow top tube (ACD solution A)
Minimum:
Preferred Minimum: 3 mL whole blood from lavender top(EDTA) tube
Absolute Minimum: 1 mL whole blood from lavender top(EDTA) tube
Rejection Criteria:
Frozen specimens
Analytic Time:
1 week upon receipt at reference laboratory
Reference Range:
By report
Interpretive Data:
Background Information for UDP Glucuronosyltransferase 1A1 (UGT1A1)
Genotyping:
Characteristics: UGT1A1 is responsible for the clearance of drugs
(e.g., irinotecan) and endbiotic compounds (e.g., bilirubin).
Irinotecan's major active and toxic metabolite (SN-38) is inactivated
by UGT1A1 and then eliminated via the bile. UGT1A1 gene mutations
cause accumulation of SN-38, which may lead to irinotecan-related
toxicities (neutropenia, diarrhea).
Cause: Variations in TA repeat number in the TATAAA element of the 5'
UGT1A1-promoter affects transcription efficiency. The common number of
repeats is six [(TA) 6, *1 allele], while seven repeats [(TA) 7, *28
allele] is associated with reduced transcription activity.
Homozygosity for the (TA) 7 allele is also associated with Gilbert's
syndrome (benign familial hyperbilirubinemia).
Alleles detected: (TA)5, (TA)6, (TA)7 and (TA)8.
Clinical Sensitivity/Specificity: The risk of irinotecan toxicity by
genotype is shown below (based on data from Br J Cancer (2004)
91:678-82).
TA genotype Diarrhea Neutropenia
6/6 (*1/*1) 17% 15%
6/7 (*1/*28) 33% 27%
7/7 (*28/*28) 70% 40%
Allelic Frequency:
*1 (TA)6: Caucasians - 61%; Asians - 84%; African Americans - 47%
*28 (TA)7: Caucasians - 39%; Asians - 16%; African Americans - 43%
Analytical Sensitivity: Greater than 99 percent
Test
Limitations:
Variations in the UGT1A1 gene, other than those targeted, will not be
detected. Clinical significance of the rare (TA)5 and (TA)8 alleles on
risk of irinotecan toxicities is not well established.
Methodology:
Polymerase chain reaction followed by size analysis using capillary
electrophoresis.
CPT Code:
83891, 83898, 83909
